Long-Term Outcome of Anemic Lower-Risk Myelodysplastic Syndromes Without 5q Deletion Refractory to or Relapsing After Erythropoiesis-Stimulating Agents

Leukemia - United Kingdom
doi 10.1038/leu.2013.16
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

Long-Term Outcome of Immunosuppressive Therapy for Japanese Patients With Lower-Risk Myelodysplastic Syndromes

International Journal of Hematology
Hematology
2013English

Blood Consult: Treating Del(5q) Myelodysplastic Syndromes

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Cryptic 5q Deletion in a Patient With Myelodysplastic Syndrome

British Journal of Haematology
Hematology
2017English

Myelodysplastic Syndromes With a Deletion 5q Display a Characteristic Immunophenotypic Profile Suitable for Diagnostics and Response Monitoring

Haematologica
Hematology
2014English

Long-Term Outcome After Anterior Cervical Discectomy Without Fusion

European Spine Journal
SurgeryOrthopedicsSports Medicine
2007English

Effect of Long-Acting Erythropoiesis-Stimulating Agents on Hemoglobin Levels at the Initiation of Dialysis

Renal Replacement Therapy
2016English

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica
Hematology
2008English

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy